Post-treatment effects of erythropoietin and nordihydroguaiaretic acid on recovery from cisplatin-induced acute renal failure in the rat.
5-lipoxygenase inhibitor and human recombinant erythropoietin might accelerate renal recovery in cisplatin-induced acute renal failure rats. Male Sprague-Dawley rats were randomized into four groups: 1) normal controls; 2) Cisplatin group-cisplatin induced acute renal failure (ARF) plus vehicle treatment; 3) Cisplatin+nordihydroguaiaretic acid (NDGA) group-cisplatin induced ARF plus 5-lipoxygenase inhibitor treatment; 4) Cisplatin+erythropoietin (EPO) group-cisplatin induced ARF plus erythropoietin treatment. On day 10 (after 7 daily injections of NDGA or EPO), urea nitrogen and serum Cr concentrations were significantly lower in the Cisplatin+NDGA and Cisplatin+EPO groups than in the Cisplatin group, and 24 hr urine Cr clearances were significantly higher in the Cisplatin+EPO group than in the Cisplatin group. Semi-quantitative assessments of histological lesions did not produce any significant differences between the three treatment groups. Numbers of PCNA(+) cells were significantly higher in Cisplatin, Cisplatin+NDGA, and Cisplatin+EPO groups than in normal controls. Those PCNA(+) cells were significantly increased in Cisplatin+NDGA group. These results suggest that EPO and also NDGA accelerate renal function recovery by stimulating tubular epithelial cell regeneration.
Lee
Dong Won
DW
Department of Internal Medicine, Pusan National University School of Medicine, Seo-gu, Busan, Korea.
Kwak
Ihm Soo
IS
Lee
Soo Bong
SB
Song
Sang Heon
SH
Seong
Eun Young
EY
Yang
Byeong Yun
BY
Lee
Min Young
MY
Sol
Mee Young
MY
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000188:drug therapy*; D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000008:administration & dosage; D001806:Blood Urea Nitrogen; D002945:Cisplatin / Q000633:toxicity*; D003404:Creatinine / Q000652:urine; D004847:Epithelial Cells / Q000187:drug effects; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D007668:Kidney / Q000378:metabolism; D007684:Kidney Tubules / Q000187:drug effects; D008297:Male; D009637:Masoprocol / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012038:Regeneration
D004921:Erythropoietin; D009637:Masoprocol; D003404:Creatinine; D001094:Arachidonate 5-Lipoxygenase; D002945:Cisplatin